Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively impacting both disease burden and quality of life. The identification of certain gene conditions that contribute to MPNs has led to improvements in diagnosis and stratifying risk. Ongoing trials will further define the role of JAK inhibitors in MPNs as well as evaluate combination therapies and new targeted therapies.
CancerConnect News coverage of advances in the management of MPNs included the following key developments:
Polycythemia Vera News
- All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor
- Jakafi® Appears Safe and Effective in Long-Term Disease Control in Polycythemia Vera
- Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera
- Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera
- Jakafi® Improves Symptoms and Quality of Life in Polycythemia Vera
- Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression
- Protein Inhibitor INCB039110 Appears Active in Myelofibrosis
- International Marrow Donor Registries Reach 25 Million Potential Donors, Give Hope to Searching Blood Cancer Patients Around the World
MPN Side Effect News
- Ask the Expert: Blood Cancer Treatment Progress & What’s Next
- Ask the Expert: Polycythemia Vera
- Myeloproliferative Neoplasms: When Good Cells Go Bad
Click here for CURRENT MPN NEWS
Learning More About Myeloproliferative Neoplasms
- Sign up for monthly MPN newsletters here.
- Join the CancerConnect online support group to join ongoing discussions with other individuals affected by PV, ET and myelofibrosis here.
- Follow CancerConnect on Facebookand Twitter.
Copyright © 2017 CancerConnect. All Rights Reserved.